12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IPI-145: Additional Phase I data

Data from 22 evaluable patients with chronic lymphocytic leukemia (CLL) in an open-label, U.S. Phase I trial showed that twice-daily oral IPI-145 produced 12 partial responses (PRs). Median time to response was 1.9 months. In 4 evaluable CLL patients with deletion of chromosome 17 (del17p), IPI-145 led to 2 PRs and 1 case of stable disease (SD). In 6 evaluable CLL patients with a p53 mutation, IPI-145 led to 4 PRs. Separately, Infinity reported data from 47 evaluable patients with B and T cell lymphomas in the trial. In 19 evaluable patients with indolent...

Read the full 446 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >